BrainCheck is a U.S. FDA computerized cognitive assessment aid. The company provides reimbursable neuropsychological tests to aid in identifying dementia and cognitive impairment.
BrainCheck allows users to track their brain health for significant changes and share results with clinicians.
BrainCheck was founded in 2014 by Yael Katz & David Eagleman. The company is headquartered in Houston, Texas.
BrainCheck’s mission is to help physicians deliver the highest quality, person-centered cognitive care, and to help people of all ages understand what’s happening in their brain.
BrainCheck provides clinical decision support, mapping specific cognitive impairments to areas where a patient is likely to struggle in daily life.
BrainCheck provides cognitive health solutions to over 100 healthcare and athletic organizations around the country. And more than 40,000 individuals are using BrainCheck to assess and monitor their cognitive health and share changes with clinicians.
BrainCheck is backed by S3 Ventures, Tensility Venture Partners, True Wealth Ventures and others. The company raised $8M from a "Series A" financing on Oct 8, 2019. The round brings BrainCheck's total funding to $14.7M to date.